The Company and Summary of Significant Accounting Policies (Details Textual)			12 Months Ended
	Jan. 11, 2017 USD ($)	Jun. 16, 2015 USD ($)	Dec. 31, 2016 USD ($) Patients Segment shares	Dec. 31, 2015 USD ($) shares
Company And Summary Of Significant Accounting Policies Table [Line Items]
Date of completion of business combination with Nuvelo			Jan. 27, 2009
Revenues			$ 0
Proceeds from sale of common stock				$ 37,000,000
Excess tax benefits from share-based payments			$ 0	$ 0
Number of shares withhold to satisfy statutory income tax withholding obligations | shares			0	0
Concentrations of credit risk			$ 0
Number of segments | Segment			1
Private Investment In Public Entity Transaction
Company And Summary Of Significant Accounting Policies Table [Line Items]
Proceeds from the issuance of security units		$ 34,200,000
At the Market Offering under Sales Agreement | Subsequent Event
Company And Summary Of Significant Accounting Policies Table [Line Items]
Aggregate offering price of common stock authorized	$ 7,300,000
Proceeds from sale of common stock	$ 0
Phase 3 | BEST Trial
Company And Summary Of Significant Accounting Policies Table [Line Items]
Number of patients | Patients			2,708
Phase 2B/Phase 3 | GENETIC-AF Trial
Company And Summary Of Significant Accounting Policies Table [Line Items]
Number of patients company plans to enroll | Patients			620
Trial endpoint, term			168 days